Hyperprolactinemia: Causes, diagnosis, and treatment;Hiperprolaktynemia: przyczyny, diagnostyka, leczenie

Endokrynologia Polska

Volumn 57, Issue 6, 2006, Pages 656-662

  Karasek, Michał ^a,b   Pawlikowski, Marek ^a   Lewiński, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Hyperprolactinemia; Pituitary adenomas; Prolactin

Indexed keywords

AMINOQUINOLINE DERIVATIVE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; PROLACTIN; QUINAGOLIDE;

ANIMAL; BLOOD; DRUG EFFECT; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PATHOPHYSIOLOGY; RADIOGRAPHY; REVIEW; TREATMENT OUTCOME;

AMINOQUINOLINES; ANIMALS; DOPAMINE AGONISTS; ERGOLINES; HUMANS; HYPERPROLACTINEMIA; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PROLACTIN; TREATMENT OUTCOME;

EID: 34250637636     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Freeman ME, Kanyicska B, Lerant A i wsp. Prolactin structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631.
2. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42: 175-192.
3. Pawlikowski M, Kunert-Radek J, Stepień H. Direct antiproliferative effect of dopamine agonists on the anterior pituitary gland in organ culture. J Endocrinol 1978; 79: 245-246.
4. Lewiński A, Konopacki J, Pawlikowski M i wsp. Effect of intraventricular injections of 6-hydroxydopamine on anterior pituitary cell proliferation. Anat Record 1984; 209: 421-426.
5. Kelly MA, Rubinstein M, Asa SL i wsp. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997; 19: 103-113.
6. Ruberg M, Rotsztajn WH, Aracibia S i wsp. Stimulation of prolactin release by vasoactive intestinal peptide. Eur J Pharmacol 1978; 51: 319-320.
7. Ruberg M, Enjalbert A, Arancibia S i wsp. Regulation of prolactin secretion at the pituitary level. Exp Brain Res 1981; 3: 182-199.
8. Aguilera G, Hyde CL, Catt KJ. Angiotensin II receptors and prolactin release in pituitary lactotrophs. Endocrinology 1982; 111: 1045-1050.
9. Pawlikowski M, Mucha S, Kunert-Radek J i wsp. Is estrogeninduced pituitary hyperplasia and hyperprolactinaemia mediated by angiotensin II? W: Mukhopadyay AK, Raizada MK (red.). Renin-angiotensin systems. Plenum Press, New York 1995: 371-378.
10. Elias KA, Weiner RI. Direct arterial vascularization of estrogeninduced prolactin secreting anterior pituitary tumors. Proc Natl Acad Sci USA 1984; 81: 4549-4553.
11. Inder WJ. Hyperprolactinemia - differential diagnosis, investigation and management. Business Briefing: Eur Endocrine Rev 2006: 76-79.
12. Karasek M, Pawlikowski M. Hyperprolactinemia - the Essentials. Touch Briefings: European Endocrine Disease 2006: 53-59.
13. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003; 112: 1603-1618.
14. Pawlikowski M. Choroby układu podwzgórzowo-przysadkowego. W: Pawlikowski M (red.). Zarys endokrynologii klinicznej. PZWL, Warszawa 1996.
15. Faglia G. Prolactinomas and hyperprolactinemic syndrome. W: De Groot LJ, Jameson J (red.). Endocrinology, wyd. 4, cz. 1, WB Saunders, Philadelphia 2001: 329-342.
16. Serri O, Chik CL, Ur E i wsp. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575-581.
17. De Rosa M, Zarrilli S, Di Sarno A i wsp. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 2003; 20: 75-82.
18. Waldstreicher J, Duffy JF, Brown EN i wsp. Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 1483-1487.
19. Di Sarno A, Rota F, Auriemma R i wsp. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? J Endocrinol Invest 2003; 26 (supl. 7): 39-47.
20. Whittaker PG, Wilkox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big prolactin. J Clin Endocrinol Metab 1981; 53: 863-866.
21. Jackson RD, Wortsman J, Malarkey WB. Macroprolactinemia presenting like a pituitary tumor. Am J Med 1985; 78: 346-350.
22. Hattori N. Macroprolactinemia: a new case of hyperprolactinemia. J Pharmacol Sci 2003; 92: 171-177.
23. Barlier A, Jaquet P. Quinagolide - a valuable treatment option for hyperprolactinemia. Eur J Endocrinol 2006; 154: 187-195.
24. Berinder K, Stackenäs I, Akre O i wsp. Hyperprolactinemia in 271 women: up to three decades of clinical follow up. Clin Endocrinol (Oxf) 2005; 63: 450-455.
25. Losa M, Mortini P, Ribotto R i wsp. Therapeutic options in patients with microprolactinoma. Business Briefing: Eur Endocrine Rev 2006: 79-80.